Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Garry G Graham

Showing results (11-20 of 50) with videos related to

Pageof 5
Sort By:
Current Rheumatology Reports|June 23, 2018
Predicting Response or Non-response to Urate-Lowering Therapy in Patients with GoutGarry G Graham, Sophie L Stocker, Diluk R W Kannangara, et al.
Drug Safety|July 19, 2008
A benefit-risk assessment of benzbromarone in the treatment of gout. Was its withdrawal from the market in the best interest of patients?Ming-Han H Lee, Garry G Graham, Kenneth M Williams, et al.
Therapeutic Advances in Psychopharmacology|April 9, 2019
Restarting antidepressant and antipsychotic medication after intentional overdoses: need for evidence-based guidanceEmma Tay, Andreas Sotiriou, Garry G Graham, et al.
Inflammopharmacology|May 31, 2013
The modern pharmacology of paracetamol: therapeutic actions, mechanism of action, metabolism, toxicity and recent pharmacological findingsGarry G Graham, Michael J Davies, Richard O Day, et al.
Clinical Pharmacokinetics|October 19, 2016
Clinical Pharmacokinetics and Pharmacodynamics of FebuxostatBishoy Kamel, Garry G Graham, Kenneth M Williams, et al.
European Journal of Clinical Pharmacology|December 25, 2010
Lack of effect of hydrochlorothiazide and low-dose aspirin on the renal clearance of urate and oxypurinol after a single dose of allopurinol in normal volunteersDaniel Y Ng, Sophie L Stocker, Garry G Graham, et al.
Clinical Science (London, England : 1979)|November 1, 2016
Xanthine oxidoreductase and its inhibitors: relevance for goutRichard O Day, Bishoy Kamel, Diluk R W Kannangara, et al.
Clinical Pharmacokinetics|January 16, 2008
Pharmacokinetic and pharmacodynamic interaction between allopurinol and probenecid in healthy subjectsSophie L Stocker, Kenneth M Williams, Andrew J McLachlan, et al.
Journal of Medical Case Reports|November 20, 2014
Multiple episodes of aspirin overdose in an individual patient: a case reportDebasish Ghosh, Kenneth M Williams, Garry G Graham, et al.
The Journal of Rheumatology|February 3, 2011
Pharmacokinetic and pharmacodynamic interaction between allopurinol and probenecid in patients with goutSophie L Stocker, Garry G Graham, Andrew J McLachlan, et al.
Pageof 5

Showing results (11-20 of 50) with videos related to

Sort By:
Pageof 5
Current Rheumatology Reports|June 23, 2018
Predicting Response or Non-response to Urate-Lowering Therapy in Patients with GoutGarry G Graham, Sophie L Stocker, Diluk R W Kannangara, et al.
Drug Safety|July 19, 2008
A benefit-risk assessment of benzbromarone in the treatment of gout. Was its withdrawal from the market in the best interest of patients?Ming-Han H Lee, Garry G Graham, Kenneth M Williams, et al.
Therapeutic Advances in Psychopharmacology|April 9, 2019
Restarting antidepressant and antipsychotic medication after intentional overdoses: need for evidence-based guidanceEmma Tay, Andreas Sotiriou, Garry G Graham, et al.
Inflammopharmacology|May 31, 2013
The modern pharmacology of paracetamol: therapeutic actions, mechanism of action, metabolism, toxicity and recent pharmacological findingsGarry G Graham, Michael J Davies, Richard O Day, et al.
Clinical Pharmacokinetics|October 19, 2016
Clinical Pharmacokinetics and Pharmacodynamics of FebuxostatBishoy Kamel, Garry G Graham, Kenneth M Williams, et al.
European Journal of Clinical Pharmacology|December 25, 2010
Lack of effect of hydrochlorothiazide and low-dose aspirin on the renal clearance of urate and oxypurinol after a single dose of allopurinol in normal volunteersDaniel Y Ng, Sophie L Stocker, Garry G Graham, et al.
Clinical Science (London, England : 1979)|November 1, 2016
Xanthine oxidoreductase and its inhibitors: relevance for goutRichard O Day, Bishoy Kamel, Diluk R W Kannangara, et al.
Clinical Pharmacokinetics|January 16, 2008
Pharmacokinetic and pharmacodynamic interaction between allopurinol and probenecid in healthy subjectsSophie L Stocker, Kenneth M Williams, Andrew J McLachlan, et al.
Journal of Medical Case Reports|November 20, 2014
Multiple episodes of aspirin overdose in an individual patient: a case reportDebasish Ghosh, Kenneth M Williams, Garry G Graham, et al.
The Journal of Rheumatology|February 3, 2011
Pharmacokinetic and pharmacodynamic interaction between allopurinol and probenecid in patients with goutSophie L Stocker, Garry G Graham, Andrew J McLachlan, et al.
Pageof 5